But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
But large gains for some big pharma players flatter the overall figures.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Big questions now include details about a US registry and its impact on initial sales.
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Pivotal data on the Alzheimer’s project beat expectations, raising hopes for a swift reimbursement U-turn.